60 related articles for article (PubMed ID: 22215903)
1. Revisiting the role of ABC transporters in multidrug-resistant cancer.
Robey RW; Pluchino KM; Hall MD; Fojo AT; Bates SE; Gottesman MM
Nat Rev Cancer; 2018 Jul; 18(7):452-464. PubMed ID: 29643473
[TBL] [Abstract][Full Text] [Related]
2. A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy.
Bryant KG; Chae YC; Martinez RL; Gordon JC; Elokely KM; Kossenkov AV; Grant S; Childers WE; Abou-Gharbia M; Altieri DC
Oncotarget; 2017 Dec; 8(68):112184-112198. PubMed ID: 29348817
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.
Françoso A; Simioni PU
Drug Des Devel Ther; 2017; 11():177-184. PubMed ID: 28138221
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.
Silva AP; Coelho PV; Anazetti M; Simioni PU
Hum Vaccin Immunother; 2017 Apr; 13(4):843-853. PubMed ID: 27831000
[TBL] [Abstract][Full Text] [Related]
5. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.
Gu X; Chen N; Wei C; Liu S; Papadimitrakopoulou VA; Herbst RS; Lee JJ
Stat Biosci; 2016 Jun; 8(1):99-128. PubMed ID: 27617040
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.
Serkova NJ; Eckhardt SG
Front Oncol; 2016; 6():152. PubMed ID: 27471678
[TBL] [Abstract][Full Text] [Related]
7. Pragmatic medicine in solid cancer: a translational alternative to precision medicine.
Brábek J; Rosel D; Fernandes M
Onco Targets Ther; 2016; 9():1839-55. PubMed ID: 27103822
[TBL] [Abstract][Full Text] [Related]
8. Dogs as a Model for Cancer.
Gardner HL; Fenger JM; London CA
Annu Rev Anim Biosci; 2016; 4():199-222. PubMed ID: 26566160
[TBL] [Abstract][Full Text] [Related]
9. Anticancer cardamonin analogs suppress the activation of NF-kappaB pathway in lung cancer cells.
He W; Jiang Y; Zhang X; Zhang Y; Ji H; Zhang N
Mol Cell Biochem; 2014 Apr; 389(1-2):25-33. PubMed ID: 24390014
[TBL] [Abstract][Full Text] [Related]
10. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.
Mossé YP; Lipsitz E; Fox E; Teachey DT; Maris JM; Weigel B; Adamson PC; Ingle MA; Ahern CH; Blaney SM
Clin Cancer Res; 2012 Nov; 18(21):6058-64. PubMed ID: 22988055
[TBL] [Abstract][Full Text] [Related]
11. Mathematical and statistical modeling in cancer systems biology.
Blair RH; Trichler DL; Gaille DP
Front Physiol; 2012; 3():227. PubMed ID: 22754537
[TBL] [Abstract][Full Text] [Related]
12. Discovery of small molecule cancer drugs: successes, challenges and opportunities.
Hoelder S; Clarke PA; Workman P
Mol Oncol; 2012 Apr; 6(2):155-76. PubMed ID: 22440008
[TBL] [Abstract][Full Text] [Related]
13. Hsp90 molecular chaperone inhibitors: are we there yet?
Neckers L; Workman P
Clin Cancer Res; 2012 Jan; 18(1):64-76. PubMed ID: 22215907
[TBL] [Abstract][Full Text] [Related]
14. Drug development: portals of discovery.
Bates SE; Amiri-Kordestani L; Giaccone G
Clin Cancer Res; 2012 Jan; 18(1):23-32. PubMed ID: 22215903
[TBL] [Abstract][Full Text] [Related]
15. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
17. Virtual screening and further development of novel ALK inhibitors.
Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
[TBL] [Abstract][Full Text] [Related]
18. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
Nelson MH; Dolder CR
Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
